Your browser doesn't support javascript.
loading
Disparity in the use of Alzheimer's disease treatment in Southern Brazil.
De Marco, Maisa; Brandi, Ana Laura; Bieger, Andrei; Krug, Bárbara; Camozzato, Analuiza; Picon, Paulo D; Chaves, Marcia Lorena Fagundes; Castilhos, Raphael Machado.
Afiliação
  • De Marco M; Graduate Program in Medical Sciences, Universidade Federal do Rio Grande Sul, Porto Alegre, Rio Grande do Sul, 90035003, Brazil.
  • Brandi AL; Faculdade de Medicina, Universidade Federal do Rio Grande Sul, Porto Alegre, Rio Grande do Sul, 90035003, Brazil.
  • Bieger A; Biochemistry Department, Universidade Federal do Rio Grande Sul, Porto Alegre, Rio Grande do Sul, 90040060, Brazil.
  • Krug B; Secretaria Estadual de Saúde do Estado do Rio Grande do Sul, Porto Alegre, Rio Grande do Sul, 90110150, Brazil.
  • Camozzato A; Department of Psychiatry, Universidade Federal de Ciências da Saúde de Porto Alegre (UFCSPA), Porto Alegre, Rio Grande do Sul, 90050170, Brazil.
  • Picon PD; Department of Internal Medicine, Universidade Federal do Rio Grande do Sul (UFRGS), Porto Alegre, Rio Grande do Sul, 90035903, Brazil.
  • Chaves MLF; Department of Internal Medicine, Universidade Federal do Rio Grande do Sul (UFRGS), Porto Alegre, Rio Grande do Sul, 90035903, Brazil.
  • Castilhos RM; Cognitive and Behavioral Neurology Center, Division of Neurology, Hospital de Clínicas de Porto Alegre, Ramiro Barcelos Street 2350, Porto Alegre, Rio Grande do Sul, 90035903, Brazil.
Sci Rep ; 13(1): 9555, 2023 06 12.
Article em En | MEDLINE | ID: mdl-37308535
Alzheimer's disease (AD) treatment is freely available in the Brazilian public health system. However, the prescription pattern and its associated factors have been poorly studied in our country. We reviewed all granted requests for AD treatment in the public health system in October 2021 in the Rio Grande do Sul (RS) state, Southern Brazil. We performed a spatial autocorrelation analysis with the population-adjusted patients receiving any AD medication as the outcome and correlated it with several socioeconomic variables. 2382 patients with AD were being treated during the period analyzed. The distribution of the outcome variable was not random (Moran's I 0.17562, P <.0001), with the most developed regions having a higher number of patients/100,000 receiving any AD medication. We show that although AD medications are available through the public health system, there is a clear disparity between regions of RS state. Factors related to socioeconomic development partly explain this finding.
Assuntos
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doença de Alzheimer Limite: Humans País/Região como assunto: America do sul / Brasil Idioma: En Revista: Sci Rep Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Brasil País de publicação: Reino Unido
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doença de Alzheimer Limite: Humans País/Região como assunto: America do sul / Brasil Idioma: En Revista: Sci Rep Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Brasil País de publicação: Reino Unido